6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
This manuscript describes the Advanced Breast Cancer (ABC) international consensus guidelines updated at the last two ABC international consensus conferences (ABC 6 in 2021, virtual, and ABC 7 in 2023, in Lisbon, Portugal), organized by the ABC Global Alliance. It provides the main recommendations on how to best manage patients with advanced breast cancer (inoperable locally advanced or metastatic), of all breast cancer subtypes, as well as palliative and supportive care. These guidelines are based on available evidence or on expert opinion when a higher level of evidence is lacking. Each guideline is accompanied by the level of evidence (LoE), grade of recommendation (GoR) and percentage of consensus reached at the consensus conferences. Updated diagnostic and treatment algorithms are also provided. The guidelines represent the best management options for patients living with ABC globally, assuming accessibility to all available therapies. Their adaptation (i.e. resource-stratified guidelines) is often needed in settings where access to care is limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Hellman, S., & Weichselbaum, R. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.8 · Cited by 2,562
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Self-citationAdjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Tutt, A. N. J., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., Gelber, R. D., de Azambuja, E., Fielding, A., Balmaña, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105215 · Cited by 1,729
Self-citationSacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028485 · Cited by 1,711
Self-citationMohile, S. G., Dale, W., Somerfield, M. R., Schonberg, M. A., Boyd, C. M., Burhenn, P. S., Canin, B., Cohen, H. J., Holmes, H. M., Hopkins, J. O., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8687 · Cited by 1,479
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G. S., Biganzoli, L., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.09.010 · Cited by 1,369
Self-citationTucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
Self-citationSchmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
Self-citationSwain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30863-0 · Cited by 922
Self-citationA meta-analytic review of the effects of exercise on brain-derived neurotrophic factor
Szuhany, K. L., Bugatti, M., & Otto, M. W. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.10.003 · Cited by 909
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Turner, N. C., Oliveira, M., Howell, S. J., Dalenc, F., Cortes, J., Gomez Moreno, H. L., Hu, X., Jhaveri, K., Krivorotko, P., Loibl, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214131 · Cited by 813
Self-citationOverall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., Winer, E. P., Janni, W., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2114663 · Cited by 791
Self-citationPascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Self-citationRobson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
Self-citationBidard, F.-C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M.-A., Sohn, J. H., Taylor, D., Harnden, K. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00338 · Cited by 777
Self-citationAndré, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.011 · Cited by 624
Self-citationSaura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00147 · Cited by 604
Self-citationCancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆
Arends, J., Strasser, F., Gonella, S., Solheim, T. S., Madeddu, C., Ravasco, P., Buonaccorso, L., de van der Schueren, M. A. E., Baldwin, C., Chasen, M., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100092 · Cited by 586
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
Self-citationRugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., Trédan, O., Ciruelos, E., Dalenc, F., Gómez Pardo, P., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01245-x · Cited by 496
Self-citationPivot, X., Manikhas, A., Żurawski, B., Chmielowska, E., Karaszewska, B., Allerton, R., Chan, S., Fabi, A., Bidoli, P., Gori, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1794 · Cited by 242
Finn, R. S., Rugo, H. S., Dieras, V. C., Harbeck, N., Im, S.-A., Gelmon, K. A., Walshe, J. M., Martin, M., Chavez Mac Gregor, M., Bananis, E., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.17_suppl.lba1003 · Cited by 169
Self-citationBardia, A., Jhaveri, K., Im, S.-A., Pernas Simon, S., De Laurentiis, M., Wang, S., Martinez, N., Santos Borges, G., Cescon, D. W., Hattori, M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.015 · Cited by 43
Self-citationKisely, S., Alotiby, M. K. N., Protani, M. M., Soole, R., Arnautovska, U., & Siskind, D. (2023) · Psycho-Oncology · doi:10.1002/pon.6120 · Cited by 31
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Metadata
- Authors
- Cardoso, F., Paluch-Shimon, S., Schumacher-Wulf, E., Matos, L., Gelmon, K., Aapro, M. S., Bajpai, J., Barrios, C. H., Bergh, J., Bergsten-Nordström, E., Biganzoli, L., Cardoso, M. J., Carey, L. A., Chavez-MacGregor, M., Chidebe, R., Cortés, J., Curigliano, G., Dent, R. A., El Saghir, N. S., Eniu, A., Fallowfield, L., Francis, P. A., Franco Millan, S. X., Gilchrist, J., Gligorov, J., Gradishar, W. J., Haidinger, R., Harbeck, N., Hu, X., Kaur, R., Kiely, B., Kim, S.-B., Koppikar, S., Kuper-Hommel, M. J. J., Lecouvet, F. E., Mason, G., Mertz, S. A., Mueller, V., Myerson, C., Neciosup, S., Offersen, B. V., Ohno, S., Pagani, O., Partridge, A. H., Penault-Llorca, F., Prat, A., Rugo, H. S., Senkus, E., Sledge, G. W., Swain, S. M., Thomssen, C., Vorobiof, D. A., Vuylsteke, P., Wiseman, T., Xu, B., Costa, A., Norton, L., & Winer, E. P.
- Venue
- The Breast
- Publisher
- Elsevier BV
- Published
- 2024-08
- Volume
- 76
- Pages
- 103756
- ISSN
- 0960-9776 (ISSN-L)
- OpenAlex
- W4399068599
- Cited by
- 237
- References
- 27
- FWCI
- 36.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.